MedTrace Logo

BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy

NCT00020371 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have cancers that have not responded to previous therapy.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific
  • Neutropenia

Interventions

DRUG

BMS-247550

DRUG

filgrastim

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Jame Abraham · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00020371 on ClinicalTrials.gov